M2e-based universal influenza vaccines: a historical overview and new approaches to development
Abstract The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Journal of biomedical science - 26(2019), 1 vom: 19. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mezhenskaya, Daria [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Conserved protein |
|---|
| Anmerkungen: |
© The Author(s). 2019 |
|---|
| doi: |
10.1186/s12929-019-0572-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR028498070 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR028498070 | ||
| 003 | DE-627 | ||
| 005 | 20230520012116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12929-019-0572-3 |2 doi | |
| 035 | |a (DE-627)SPR028498070 | ||
| 035 | |a (SPR)s12929-019-0572-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mezhenskaya, Daria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a M2e-based universal influenza vaccines: a historical overview and new approaches to development |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s). 2019 | ||
| 520 | |a Abstract The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines. | ||
| 650 | 4 | |a Influenza a virus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Influenza M2 ectodomain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Conserved protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cross-protection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Universal influenza vaccine |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Isakova-Sivak, Irina |0 (orcid)0000-0002-2801-1508 |4 aut | |
| 700 | 1 | |a Rudenko, Larisa |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biomedical science |d London : BioMed Central, 1994 |g 26(2019), 1 vom: 19. Okt. |w (DE-627)SPR028485629 |w (DE-600)1482918-6 |x 1423-0127 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2019 |g number:1 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12929-019-0572-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2019 |e 1 |b 19 |c 10 | ||